Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patientsShumin Yuan, Zibing Wang, Quanli Gao et al.|Cancer Immunology Immunotherapy|2022Cited by 19
Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced MalignanciesHao Huang, Zibing Wang, Ling Peng et al.|Frontiers in Immunology|2022Cited by 6
Case Report: Eculizumab in highly active myasthenia gravis complicated by severe infectionsYufei Deng, Qilong Jiang, Xiang Yan et al.|Frontiers in Immunology|2025Cited by 1